NCT03619187撤回3 期
A Phase 3, Open-label, Multicenter Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients With Elevated Resting Heart Rate
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- Amgen
- 主要终点
- pVO2
研究概览
简要总结
The hypothesis is that the treatment with ivabradine will increase pVO2 after 16 weeks of treatment compared to baseline in the heart transplant recipient population with elevated resting HR.
详细描述
The primary goal of this study is to assess the impact of ivabradine on cardiopulmonary exercise capacity in heart transplant recipients with elevated resting heart rate (HR).
Exercise capacity will be assessed by the determination of the peak oxygen consumption (pVO2) during standard cardiopulmonary exercise test before and after the treatment period with ivabradine. The secondary goal is to determine HR reduction with ivabradine in the patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject has provided informed consent/assent prior to initiation of any study-specific activities/procedures
- •Male or female, ≥ 18 to ≤ 70 years of age at signing of informed consent
- •History of heart transplantation within 1 to 4 years from screening
- •Sinus rhythm and elevated resting HR > 95 bpm at screening (ECG)
- •Able to perform exercise testing as required per protocol, per the investigator, at time of screening
- •Peak VO2 < 70% of the predicted normal value for age and gender with respiratory exchange ratio (RER) ≥ 1.05, from a CPET conducted during screening
排除标准
- •Participation in a cardiac rehabilitation program during the study period
- •Treatment for heart transplant rejection within the previous 3 months before screening
- •Severe allograft vasculopathy limiting the tolerance of CPET at time of screening
- •During CPET at screening, significant adverse finding (eg, exercise-induced early ischemic changes, abnormal blood pressure response, unexpected arrhythmia or other serious finding) that precludes safe participation in the study, per investigator
- •Sick sinus syndrome, sinoatrial block and/or third degree atrioventricular block, unless a functioning demand pacemaker is present, or pacemaker dependency at screening
- •Resting systolic blood pressure >160 mmHg or <100 mmHg, or diastolic blood pressure >90 mmHg at screening
- •History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
- •Presence of clinically meaningful acute or chronic infection, per investigator, at screening
- •Major medical event or procedure (as determined by investigator) within 3 months prior to screening
- •Previously received ivabradine after heart transplantation (prior to the participation in this study)
- •Subjects taking QT prolonging medicinal products for cardiovascular (eg, but not limited to, quinidine, disopyramide, bepridil, sotalol, ibutilide) or non-cardiovascular disease (eg, but not limited to, pimozide, ziprasidone, sertindole, mefloquine, halofantrine, pentamidine, cisapride, intravenous (IV) erythromycin)
- •Subjects should not be receiving beta-blockers, diltiazem, or verapamil for at least 7 days before screening
- •Subjects exposed to a strong Cytochrome P450 3A4 (CYP3A4) inhibitor (examples of strong CYP3A4 inhibitors include; azole antifungals [eg, itraconazole], macrolide antibiotics [eg, clarithromycin, telithromycin], human immunodeficiency virus protease inhibitors, [eg, nelfinavir], and nefazodone]) within 14 days prior to screening, or to a strong CYP3A4 inducer (examples of CYP3A4 inducers include; St. John's wort, rifampicin, barbiturates, and phenytoin) within 28 days prior to screening
- •Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
- •Hemoglobin < 8 g/dL at screening (or within 3 months prior to screening if no clinically meaningful event, as determined by the investigator, has occurred in that period) and not expected to receive blood transfusion during the study
- •Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease [MDRD] equation) at screening (or within 3 months prior to screening)
- •Subject has known sensitivity to any of the products to be administered during dosing
- •Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 2 weeks after the last dose of investigational product
- •Female subjects of childbearing potential unwilling to use 1 highly effective method of contraception during treatment and for an additional 2 weeks after the last dose of investigational product. Refer to Section 12.5 for additional contraceptive information
- •Female subjects of childbearing potential with a positive pregnancy test assessed at screening by a serum pregnancy test
研究组 & 干预措施
Single Arm
Experimental
Study Product
干预措施: Ivabradine (Drug)
结局指标
主要结局
pVO2
时间窗: Week 16
To evaluate the effect of treatment with ivabradine on exercise capacity as measured by peak oxygen consumption (pVO2)
次要结局
- Resting Heart Rate(Week 16)
研究者
相似试验
已完成
3 期
IvaBRAdine blocK of Funny Current for Heart Rate Control in permanEnt Atrial Fibrillation. (BRAKE-AF Study).Heart DiseasesAtrial FibrillationNCT03718273Adolfo Fontenla68
已完成
3 期
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerTriple Negative Breast CancerNCT02032277AbbVie634
招募中
2 期
A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type IIMucopolysaccharidosis Type IIMetabolic DiseasesNCT05208281AO GENERIUM32
已完成
1 期
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT02944396AbbVie25
进行中（未招募）
3 期
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia AHemophilia ANCT04644575Bioverativ, a Sanofi company261